Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Centro de investigaciones y Publicaciones Farmacéuticas
2008
|
| Subjects: | |
| Online Access: | https://www.redalyc.org/articulo.oa?id=69060204 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866567485729275904 |
|---|---|
| author | Thomas Delate |
| author_facet | Thomas Delate |
| contents | Patient factors associated with hemoglobin a1c change with pioglitazone as adjunctive therapy in type 2 diabetes mellitus Thomas Delate Mongthuong T. Tran Shakti Bachmann Medicina Type 2 United States Diabetes Mellitus Thiazolidinediones Regression Analysis Objective: To identify patient factors associated withchange in hemoglobin A1C (A1C) with adjunctpioglitazone therapy in routine clinical practice.Methods: This was a retrospective analysis of adulttype 2 diabetes mellitus patients in a healthmaintenance organization setting who were newlyinitiatedon pioglitazone between January 2002 andDecember 2005. Eligible patients were receiving atleast one other oral antihyperglycemic medicationprior to initiating pioglitazone and maintained astable dose of pioglitazone for 90 days. Data oneligible patients characteristics, pharmacypurchases, comorbidities, and A1C measurement90 days prior to the pioglitazone purchase date(baseline) and 90 days after achieving a stable dose(follow-up) were obtained from electronic records.Multivariate regression modeling was used toassess factors independently associated with: 1)absolute change in A1C, 2) achieving a ≥1percentage point decrease in A1C, and 3) achievingan A1C<7%.Results: Baseline and follow-up A1Cs wereavailable for 128 patients. At baseline, mean agewas 65 years, 38% were female, mean A1C was8.4%, and 74% had an A1C>8%. At follow-up, themean A1C change was -1.2 percentage points(interquartile range= -0.4, -2.1), 59% achieved a ≥1unit decrease in A1C, and 44% achieved anA1C<7%. Independent predictors in all models werebaseline A1C and time (in days) between baselineand follow-up A1C measurements (p<0.05).Conclusions: Adjunct pioglitazone therapy in routineclinical practice was associated with clinicallymeaningful reductions in A1C levels. Patients withhigher baseline A1C achieved the greatest absolutereduction in A1C but were less likely to achievelevels <7% 2008 artículo científico 1885-642X https://www.redalyc.org/articulo.oa?id=69060204 en http://www.redalyc.org/revista.oa?id=690 Pharmacy Practice application/pdf Centro de investigaciones y Publicaciones Farmacéuticas Pharmacy Practice (España) Num.2 Vol.6 |
| format | Artículo científico |
| id | redalyc_69060204 |
| language | en |
| publishDate | 2008 |
| publisher | Centro de investigaciones y Publicaciones Farmacéuticas |
| spellingShingle | Patient factors associated with hemoglobin a1c change with pioglitazone as adjunctive therapy in type 2 diabetes mellitus Thomas Delate Medicina Type 2 United States Diabetes Mellitus Thiazolidinediones Regression Analysis Patient factors associated with hemoglobin a1c change with pioglitazone as adjunctive therapy in type 2 diabetes mellitus Thomas Delate Mongthuong T. Tran Shakti Bachmann Medicina Type 2 United States Diabetes Mellitus Thiazolidinediones Regression Analysis Objective: To identify patient factors associated withchange in hemoglobin A1C (A1C) with adjunctpioglitazone therapy in routine clinical practice.Methods: This was a retrospective analysis of adulttype 2 diabetes mellitus patients in a healthmaintenance organization setting who were newlyinitiatedon pioglitazone between January 2002 andDecember 2005. Eligible patients were receiving atleast one other oral antihyperglycemic medicationprior to initiating pioglitazone and maintained astable dose of pioglitazone for 90 days. Data oneligible patients characteristics, pharmacypurchases, comorbidities, and A1C measurement90 days prior to the pioglitazone purchase date(baseline) and 90 days after achieving a stable dose(follow-up) were obtained from electronic records.Multivariate regression modeling was used toassess factors independently associated with: 1)absolute change in A1C, 2) achieving a ≥1percentage point decrease in A1C, and 3) achievingan A1C<7%.Results: Baseline and follow-up A1Cs wereavailable for 128 patients. At baseline, mean agewas 65 years, 38% were female, mean A1C was8.4%, and 74% had an A1C>8%. At follow-up, themean A1C change was -1.2 percentage points(interquartile range= -0.4, -2.1), 59% achieved a ≥1unit decrease in A1C, and 44% achieved anA1C<7%. Independent predictors in all models werebaseline A1C and time (in days) between baselineand follow-up A1C measurements (p<0.05).Conclusions: Adjunct pioglitazone therapy in routineclinical practice was associated with clinicallymeaningful reductions in A1C levels. Patients withhigher baseline A1C achieved the greatest absolutereduction in A1C but were less likely to achievelevels <7% 2008 artículo científico 1885-642X https://www.redalyc.org/articulo.oa?id=69060204 en http://www.redalyc.org/revista.oa?id=690 Pharmacy Practice application/pdf Centro de investigaciones y Publicaciones Farmacéuticas Pharmacy Practice (España) Num.2 Vol.6 |
| title | Patient factors associated with hemoglobin a1c change with pioglitazone as adjunctive therapy in type 2 diabetes mellitus |
| topic | Medicina Type 2 United States Diabetes Mellitus Thiazolidinediones Regression Analysis |
| url | https://www.redalyc.org/articulo.oa?id=69060204 |